A Phase 3 interventional study of botulinum toxin neuromodulator in Glabellar Lines and Lateral Canthal Lines, sponsored by Galderma R&D. Completed at 30 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-18.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a phase 3, multicenter, open-label study to evaluate the safety of QM1114-DP for the long term treatment of moderate to severe Glabellar (Frown) Lines (GL) and Lateral Canthal Lines (Crow's Feet and LCL).
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The investigational product (QM1114-DP) is a BoNT Type A. At each treatment a total dose of QM1114-DP will be administered in the glabella and lateral canthal lines.
Biological: botulinum toxin neuromodulator
A dose of QM1114-DP will be injected in the GL area and in the LCL area.
Also known as: QM1114-DP
Percentage of Subjects Who Achieve Grade/Level 0 or 1 on the GL Investigator Scales at Maximum Frown
4-point scale
Time frame: Week 4
Percentage of Subjects Who Achieve Grade/Level 0 or 1 on the LCL Investigator Scales at Maximum Smile
4-point scale
Time frame: Week 4
| Milestone | QM1114-DP in the LCL and the GL Areas |
|---|---|
| Started | 902 |
| Completed | 790 |
| Not completed | 112 |
4-point scale
| Participants | QM1114-DP in the GL |
|---|---|
| Percentage of Subjects Who Achieve Grade/Level 0 or 1 on the GL Investigator Scales at Maximum Frown | 769 |
4-point scale
| Participants | QM1114-DP in the LCL |
|---|---|
| Percentage of Subjects Who Achieve Grade/Level 0 or 1 on the LCL Investigator Scales at Maximum Smile | 719 |
Collected over 12 months. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| QM1114-DP in the LCL and the GL Areas | 1/902 (0.1%) | 23/902 (2.5%) | 243/902 (26.9%) |
| Event | QM1114-DP in the LCL and the GL Areas |
|---|---|
| AppendicitisInfections and infestations | 1/902 |
| COVID-19Infections and infestations | 1/902 |
| Cholecystitis infectiveInfections and infestations | 1/902 |
| Post procedural infectionInfections and infestations | 1/902 |
| Urinary Tract InfectionInfections and infestations | 1/902 |
| UrosepsisInfections and infestations | 1/902 |
| Abdominal Pain UpperGastrointestinal disorders | 1/902 |
| Gastric ulcerGastrointestinal disorders | 1/902 |
| Gastrointestinal perforationGastrointestinal disorders | 1/902 |
| Adnocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/902 |
| Event | QM1114-DP in the LCL and the GL Areas |
|---|---|
| Injection site PainGeneral disorders | 65/902 |
| Injection site bruisingGeneral disorders | 59/902 |
| HeadacheNervous system disorders | 54/902 |
| COVID-19Infections and infestations | 48/902 |
| HypertensionVascular disorders | 19/902 |
| Alanine aminotransferase increasedInvestigations | 16/902 |
| Upper respiratory tract infectionInfections and infestations | 15/902 |
| Urinary Tract InfectionInfections and infestations | 15/902 |
| Aspartate aminotransferase increasedInvestigations | 15/902 |
| Gamma-glutamyltransferase increasedInvestigations | 10/902 |
| Age, Continuous(years) | QM1114-DP in the LCL and the GL Areas |
|---|---|
| Mean | 47.2 ± 11.56 |
| Sex: Female, Male(Participants) | QM1114-DP in the LCL and the GL Areas |
|---|---|
| Female | 775 |
| Male | 127 |
| Race (NIH/OMB)(Participants) | QM1114-DP in the LCL and the GL Areas |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 12 |
| Native Hawaiian or Other Pacific Islander | 5 |
| Black or African American | 26 |
| White | 820 |
| More than one race | 16 |
| Unknown or Not Reported | 22 |
| Region of Enrollment(participants) | QM1114-DP in the LCL and the GL Areas |
|---|---|
| United States | 902 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2020 to primary completion in Apr 2021, 14 months.
Results were first posted in Jun 2023, 2 years 2 months after primary completion. A results delay was requested in May 2021.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A